Curtis Garbett

Curtis Garbett
Curtis Garbett has been a bladder cancer patient since February 2015 and was diagnosed with Stage IV bladder cancer in December 2015. He also has an FGFR mutation that was detected through genomic testing and has participated in clinical trials that study the effects of an FGFR inhibitor on bladder cancer. Curtis is currently the first patient to have urothelial carcinoma move to the bile duct and is undergoing treatment with excellent results. Read more.